GlassScriptPhysician profile
Eric J Milie
NPI 1396795100
$2,334.85
in general payments reported to CMS, 2019-2025
24 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $250 · 2021: $167 · 2022: $230 · 2023: $255 · 2024: $584 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $299.63 | 2023-2024 | Nayzilam, Briviact |
| Lilly USA, LLC | $297.84 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $287.89 | 2019-2024 | Xarelto |
| Alkermes, INC. | $252.00 | 2019-2025 | Vivitrol, Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.62 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Novo Nordisk INC | $176.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $171.42 | 2019-2024 | |
| Glaxosmithkline, LLC. | $71.99 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $65.75 | 2020 | |
| Novartis Pharmaceuticals Corporation | $64.57 | 2019-2022 | |
| Grifols USA, LLC | $58.75 | 2025 | Prolastin-C Liquid |
| Edwards Lifesciences Corporation | $55.71 | 2024 | |
| Inspire Medical Systems, INC. | $46.98 | 2024-2025 | Inspire |
| Eisai INC. | $35.25 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.23 | 2020-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.10 | 2019-2020 | |
| Kyowa Kirin, INC. | $28.21 | 2024 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.24 | 2024 | Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $22.36 | 2025 | Lumryz |
| Abbvie INC. | $21.58 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.19 | 2025 | Caplyta |
| Exact Sciences Corporation | $15.94 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $14.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Milie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.